Fangfang Yang

Dr. Fangfang Yang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XXXiao Xu
Xiao Xu
NZNa Zhou
Na Zhou
HLHongwei Lan
Hongwei Lan
FYFangfang Yang
Fangfang Yang
BDBowen Dong
Bowen Dong
XZXiaochun Zhang
Xiaochun Zhang
Ferroptosis is a relatively new form of programmed cell death, which can enhance the efficacy of tumor immunotherapy by regulating the tumor microenvironment (TME). In the face of the dilemma of a great difference in the efficacy of immunotherapy for gastric cancer (GC) patients, the exploration of ferroptosis may assist us in predicting immunotherapy efficacy prior to treatment. The potential role of ferroptosis in TME still needs further elucidation. Based on ferroptosis-related genes (FRGs), we systematically evaluated ferroptosis molecular subtypes in gastric cancer. Additionally, the association between these molecular subtypes and the characteristics of TME was examined. A ferroptosis score was constructed to further explore the predictive efficacy of ferroptosis on the immunotherapy response in gastric cancer. There were also 32 other cancers that were evaluated. Three molecular subtypes of ferroptosis in gastric cancer were identified. The three immunophenotypes of tumor immune inflamed, immune excluded, as well as immune desert were mostly in agreement with the TME features of these three subtypes. The individual tumor genetic variation, TME characteristics, immunotherapy response, and prognosis could be assessed by a ferroptosis score. High ferroptosis scores in gastric cancer suggest stromal activation and immunosuppression. It is noted that tumors with a low ferroptosis score are characterized by extensive tumor mutations as well as an immune activation, which are associated with an enhanced immunotherapy response and an improved prognosis. This study reveals that ferroptosis plays an integral role in the regulation of the tumor immune microenvironment. The ferroptosis score may serve as an independent prognostic factor for GC and will deepen our understanding of the TME infiltration mechanisms as well as lead to more rational immunotherapy regimens.

24 July 2026 in Translational Oncology
Verified
Journal Article
Open access
YZYuming Zhang
Yuming Zhang
XDXueqin Duan
Xueqin Duan
HHHelei Hou
Helei Hou
GWGuanqun Wang
Guanqun Wang
QLQian Lin
Qian Lin
NZNa Zhou
Na Zhou
Colorectal cancer (CRC) is the most common malignant tumor of the digestive system. Exploring effective diagnostic markers and therapeutic targets has great significance for the diagnosis and treatment of CRC. ARID1A is frequently mutated in CRC, but its prognostic value for this disease remains controversial. Therefore, our aim was to explore the biological role of ARID1A in CRC and the underlying molecular mechanisms. The clinical relevance of ARID1A in CRC was evaluated using integrating multiple biological databases and a clinical cohort. In vitro and in vivo functional assays (CCK-8, colony formation, transwell, and xenograft models) assessed its tumor-modulating effects. Autophagy was examined via transmission electron microscopy and immunofluorescence, while western blotting quantified epithelial-mesenchymal transition, autophagy-related, and signaling pathway proteins. Based on CRC mutation data from TCGA-COAD and cBioPortal, the ARID1A mutation frequency was 14% and 16%, respectively. Survival analysis showed that the low-ARID1A-expression group had a poorer prognosis than the high-expression group. In vitro and in vivo studies showed that downregulation of ARID1A promotes various malignant biological behaviors of CRC cells, including proliferation, invasion, and metastasis. These phenotypic changes were accompanied by alterations in autophagy-related markers (such as decreased Beclin1 and LC3B, and increased p62) and activation of the AKT/mTOR/p70S6K signaling pathway. In addition, analyses of clinical samples indicated that low ARID1A expression is an independent risk factor for CRC recurrence and metastasis. In summary, ARID1A has a tumor-suppressive role in CRC. These data suggest that ARID1A expression is a potential biomarker for CRC, which could lead to novel clinical diagnostic and treatment approaches.